| CCCC |
C4 Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
9.9% |
$50,277,776 |
|
22,647,647 |
|
Point72 Asset Management, L.P. |
17 Oct 2025 |
| CYBN |
CYBIN INC. |
Common Shares, no par value |
9.9% |
$37,759,482 |
+$28,298,275 |
6,410,778 |
+299% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| PTNT |
PALATIN TECHNOLOGIES INC |
Common Stock, par value $0.01 per share |
9.9% |
$23,646,750 |
|
2,307,000 |
|
Point72 Asset Management, L.P. |
12 Nov 2025 |
| IBIO |
iBio, Inc. |
Common Stock, par value $0.001 per share |
9.9% |
$9,716,600 |
|
14,289,118 |
|
Point72 Asset Management, L.P. |
22 Aug 2025 |
| QTTB |
Q32 Bio Inc. |
Common Stock, par value $0.0001 per share |
9.9% |
$8,085,220 |
|
2,057,308 |
|
Point72 Asset Management, L.P. |
17 Feb 2026 |
| XLO |
Xilio Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
9.9% |
$6,743,200 |
+$3,371,600 |
8,000,000 |
+100% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| DSGN |
Design Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
9.4% |
$50,443,118 |
+$22,810,986 |
5,372,004 |
+83% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| TNXP |
Tonix Pharmaceuticals Holding Corp. |
Common Stock, par value $0.001 per share |
9.2% |
$19,884,434 |
|
1,235,058 |
|
Point72 Asset Management, L.P. |
29 Dec 2025 |
| ANRO |
Alto Neuroscience, Inc. |
Common Stock, par value $0.0001 per share |
8.9% |
$46,600,538 |
+$15,121,326 |
2,824,275 |
+48% |
Steven A. Cohen |
31 Dec 2025 |
| ONCH |
1RT Acquisition Corp. |
Class A Ordinary Shares, par value $0.0001 per share |
8.7% |
|
|
1,500,000 |
|
Point72 Asset Management, L.P. |
03 Jul 2025 |
| OKYO |
OKYO Pharma Ltd |
Ordinary Shares, no par value |
7.9% |
$8,279,228 |
|
4,058,445 |
|
Point72 Asset Management, L.P. |
17 Feb 2026 |
| RLAY |
Relay Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
7.8% |
$50,152,476 |
+$13,993,047 |
13,445,704 |
+39% |
Point72 Asset Management, L.P. |
30 Jun 2025 |
| ANAB |
ANAPTYSBIO, INC |
Common Stock, par value $0.001 per share |
7.7% |
$49,025,259 |
+$14,013,859 |
2,368,370 |
+40% |
Point72 Asset Management, L.P. |
31 Mar 2025 |
| ZEPP |
Zepp Health Corp |
Class A Ordinary Shares, par value $0.0001 per share |
7.6% |
$401,805,282 |
+$105,511,398 |
8,777,008 |
+36% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| EDSA |
Edesa Biotech, Inc. |
Common Shares, without par value |
7.2% |
$588,000 |
|
600,000 |
|
Point72 Asset Management, L.P. |
24 Feb 2026 |
| PALI |
PALISADE BIO, INC. |
Common Stock, par value $0.01 per share |
7% |
$20,150,884 |
+$5,586,511 |
10,495,252 |
+38% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/ |
Common Stock, par value $0.001 per share |
6.9% |
$107,936,599 |
+$31,151,331 |
2,981,674 |
+41% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| IPSC |
Century Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
6.8% |
$12,817,360 |
|
5,961,563 |
|
Point72 Asset Management, L.P. |
23 Dec 2025 |
| TENX |
TENAX THERAPEUTICS, INC. |
Common Stock, par value $0.0001 per share |
6.8% |
$6,372,396 |
+$1,260,919 |
423,415 |
+25% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| CLDX |
Celldex Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
6.7% |
$90,854,558 |
|
4,464,400 |
|
Point72 Asset Management, L.P. |
02 Jul 2025 |
| FBRX |
Forte Biosciences, Inc. |
Common Stock, par value $0.001 per share |
6.3% |
$21,132,810 |
|
792,976 |
|
Point72 Asset Management, L.P. |
12 Jan 2026 |
| GLTO |
Galecto, Inc. |
Common Stock, par value $0.00001 per share |
6.3% |
$372,164 |
|
100,001 |
|
Point72 Asset Management, L.P. |
12 Nov 2025 |
| ANGO |
ANGIODYNAMICS INC |
Common Stock, par value $0.01 per share |
6.2% |
$28,588,375 |
+$4,905,719 |
2,559,389 |
+21% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| PRAX |
Praxis Precision Medicines, Inc. |
Common Stock, par value $0.0001 per share |
6.1% |
$452,667,181 |
-$145,274,958 |
1,569,309 |
-24% |
Steven A. Cohen |
31 Dec 2025 |
| IVVD |
Invivyd, Inc. |
Common Stock, par value $0.0001 per share |
6% |
$41,965,651 |
-$9,372,996 |
16,653,036 |
-18% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| IMNM |
Immunome Inc. |
Common Stock, par value $0.0001 per share |
5.9% |
$41,638,177 |
|
4,887,110 |
|
Point72 Asset Management, L.P. |
31 Jan 2025 |
|
Infinite Eagle Acquisition Corp. |
Class A Ordinary Shares, par value $0.0001 per share |
5.8% |
|
|
1,760,000 |
|
Point72 Asset Management, L.P. |
20 Jan 2026 |
| IOBT |
IO Biotech, Inc. |
Common Stock, par value $0.001 per share |
5.6% |
$2,452,108 |
|
4,027,112 |
|
Point72 Asset Management, L.P. |
05 Feb 2026 |
| MSGE |
Madison Square Garden Entertainment Corp. |
Class A Common Stock, par value $0.01 per share |
5.5% |
$72,797,952 |
|
2,239,248 |
|
Point72 Asset Management, L.P. |
31 Dec 2024 |
| KALV |
KalVista Pharmaceuticals, Inc. |
Common Stock, par value $0.001 per share |
5.5% |
$44,930,777 |
|
2,781,902 |
|
Point72 Asset Management, L.P. |
05 Jan 2026 |
| BRCB |
Black Rock Coffee Bar, Inc. |
Class A Common Stock, par value $0.00001 per share |
5.4% |
$22,629,182 |
|
948,415 |
|
Steven A. Cohen |
12 Nov 2025 |
| PGEN |
PRECIGEN, INC. |
Common Stock, no par value per share |
5.2% |
$76,841,952 |
|
18,383,242 |
|
Point72 Asset Management, L.P. |
22 Jan 2026 |
| BBNX |
Beta Bionics, Inc. |
Common Stock, par value $0.0001 per share |
5.2% |
$34,190,043 |
|
2,290,023 |
|
Point72 Asset Management, L.P. |
18 Feb 2026 |
| LION |
Lionsgate Studios Corp. |
Common Shares, no par value per share |
5.1% |
$101,210,670 |
|
14,668,213 |
|
Point72 Asset Management, L.P. |
31 Oct 2025 |
| ORIC |
Oric Pharmaceuticals, Inc. |
Common Stock, par value $0.0001 per share |
5.1% |
$23,372,809 |
|
4,401,659 |
|
Point72 Asset Management, L.P. |
29 May 2025 |
| OVID |
Ovid Therapeutics Inc. |
Common Stock, par value $0.001 per share |
5.1% |
$11,099,895 |
|
6,727,209 |
|
Point72 Asset Management, L.P. |
02 Jan 2026 |
| VNET |
VNET Group, Inc. |
Class A Ordinary Shares, par value $0.00001 per share |
5% |
$684,703,700 |
+$357,302,860 |
79,848,828 |
+109% |
Steven A. Cohen |
08 Jan 2026 |
| BILL |
BILL Holdings, Inc. |
Common Stock, par value $0.00001 per share |
5% |
$247,450,711 |
|
5,035,627 |
|
Point72 Asset Management, L.P. |
21 Nov 2025 |
| RUN |
Sunrun Inc. |
Common Stock, par value $0.0001 per share |
5% |
$78,798,749 |
|
11,503,467 |
|
Point72 Asset Management, L.P. |
26 Jun 2025 |
| SNDX |
Syndax Pharmaceuticals Inc |
Common Stock, par value $0.0001 per share |
5% |
$44,621,185 |
+$20,827,520 |
4,327,952 |
+88% |
Point72 Asset Management, L.P. |
15 Aug 2025 |
| LENZ |
LENZ Therapeutics, Inc. |
Common Stock, par value $0.00001 per share |
4.8% |
$63,244,042 |
|
1,357,751 |
|
Steven A. Cohen |
30 Sep 2025 |
| REPL |
Replimune Group, Inc. |
Common Stock, par value $0.001 per share |
4.7% |
$15,209,289 |
-$3,488,586 |
3,629,902 |
-19% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| LLYVA |
Liberty Media Corp |
Series A Liberty Live Common Stock, par value $0.01 per share |
4.6% |
$77,347,262 |
|
1,164,693 |
|
Point72 Asset Management, L.P. |
31 Dec 2024 |
| VTYX |
Ventyx Biosciences, Inc. |
Common Stock, par value $0.0001 per share |
4.5% |
$9,981,996 |
-$8,351,669 |
3,209,645 |
-46% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| RCUS |
Arcus Biosciences, Inc. |
Common Stock, par value $0.0001 per share |
4.1% |
$58,921,714 |
-$20,381,232 |
4,332,479 |
-26% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| COGT |
Cogent Biosciences, Inc. |
Common Stock, par value $0.001 per share |
4% |
$82,625,042 |
-$60,775,814 |
5,753,833 |
-42% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| ADCT |
ADC Therapeutics SA |
Common Shares, par value CHF 0.08 per share |
4% |
$18,554,083 |
-$10,422,190 |
5,014,617 |
-36% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| ALTS |
ALT5 Sigma Corp |
Common Stock, par value $0.001 per share |
4% |
|
|
4,872,756 |
|
Point72 Asset Management, L.P. |
11 Aug 2025 |
| STNE |
StoneCo Ltd. |
Class A Common Shares, par value US$0.000079365 per share |
3.9% |
$154,268,604 |
-$64,018,202 |
9,972,114 |
-29% |
Point72 Asset Management, L.P. |
30 Jun 2025 |
| BCYC |
BICYCLE THERAPEUTICS PLC |
Ordinary Shares, nominal value 0.01 GBP per share |
3.9% |
$14,882,536 |
-$15,032,008 |
1,860,317 |
-50% |
Point72 Asset Management, L.P. |
30 Jun 2025 |
| PAGS |
PagSeguro Digital Ltd. |
Class A Common Shares, par value $0.000025 per share |
3.8% |
$57,737,749 |
-$40,080,797 |
5,989,393 |
-41% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| WOLF |
WOLFSPEED, INC. |
Common Stock, par value $0.00125 per share |
3.8% |
$19,317,826 |
-$10,844,380 |
990,150 |
-36% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| KOD |
Kodiak Sciences Inc. |
Common Stock, par value $0.0001 per share |
3.5% |
$58,658,768 |
-$20,083,422 |
2,166,929 |
-26% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| AVTX |
Avalo Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
3.5% |
$10,636,159 |
-$7,228,853 |
627,502 |
-40% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| TDOC |
Teladoc Health, Inc. |
Common Stock, par value $0.001 per share |
3.3% |
$44,796,726 |
-$23,430,960 |
5,795,178 |
-34% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| ATYR |
aTYR PHARMA INC |
Common Stock, par value $0.001 per share |
3.2% |
$9,617,297 |
|
2,845,354 |
|
Point72 Asset Management, L.P. |
31 Mar 2025 |
| PEPG |
PepGen Inc. |
Common Stock, par value $0.0001 per share |
3% |
$9,551,949 |
-$2,811,415 |
2,067,432 |
-23% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| DRUG |
BRIGHT MINDS BIOSCIENCES INC. |
Common Shares, without par value |
3% |
$4,175,988 |
|
135,189 |
|
Point72 Asset Management, L.P. |
31 Dec 2024 |
| MBLY |
Mobileye Global Inc. |
Class A Common Stock, par value $0.01 per share |
2.8% |
$84,823,217 |
-$3,371,672 |
6,007,310 |
-3.8% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| TSEM |
TOWER SEMICONDUCTOR LTD |
Ordinary Shares, par value NIS 15.00 per share |
2.6% |
$206,369,650 |
-$252,010,688 |
2,854,352 |
-55% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| AMLX |
Amylyx Pharmaceuticals, Inc. |
Common Stock, par value $0.0001 per share |
2.6% |
$38,074,233 |
-$26,039,432 |
2,801,636 |
-41% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| ENTX |
Entera Bio Ltd. |
Ordinary shares, par value NIS 0.0000769 per share |
2.6% |
$2,271,583 |
-$2,915,412 |
1,183,116 |
-56% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| CTMX |
CytomX Therapeutics, Inc. |
Common Stock, par value $0.00001 per share |
2.5% |
$12,978,754 |
-$12,811,193 |
4,068,575 |
-50% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| RPD |
Rapid7, Inc. |
Common Stock, par value $0.01 per share |
2.4% |
$36,462,076 |
|
1,502,971 |
|
Point72 Asset Management, L.P. |
31 Dec 2024 |
| OLMA |
Olema Pharmaceuticals, Inc. |
Common Stock, par value $0.0001 per share |
2.3% |
$7,781,412 |
|
1,543,931 |
|
Point72 Asset Management, L.P. |
31 Mar 2025 |
| IDYA |
IDEAYA Biosciences, Inc. |
Common Stock, par value $0.0001 per share |
2.1% |
$67,953,443 |
-$94,600,552 |
1,844,556 |
-58% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| ARRY |
Array Technologies, Inc. |
Common Stock, par value $0.001 per share |
2% |
$16,159,114 |
-$24,118,877 |
3,054,653 |
-60% |
Point72 Asset Management, L.P. |
31 Mar 2025 |
| WWW |
Wolverine World Wide Inc /DE/ |
Common Stock, par value $1 per share |
1.5% |
$22,858,695 |
-$71,449,297 |
1,230,285 |
-76% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| DYN |
Dyne Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
1.5% |
$18,546,390 |
-$39,187,803 |
1,669,342 |
-68% |
Point72 Asset Management, L.P. |
31 Mar 2025 |
| CDTX |
Cidara Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
1.4% |
$99,621,000 |
-$249,731,915 |
450,000 |
-71% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| LITE |
Lumentum Holdings Inc. |
Common Stock, par value $0.001 per share |
1.3% |
$83,269,755 |
-$307,562,007 |
895,470 |
-79% |
Point72 Asset Management, L.P. |
30 Jun 2025 |
| VSTM |
Verastem, Inc. |
Common Stock, par value $0.0001 per share |
1.3% |
$7,681,601 |
-$18,090,994 |
995,026 |
-70% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| SPHR |
Sphere Entertainment Co. |
Class A Common Stock, par value $0.01 per share |
0.8% |
$13,881,584 |
-$81,500,570 |
223,464 |
-85% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| RGLS |
Regulus Therapeutics Inc. |
Common Stock, par value $0.001 per share |
0.3% |
$1,977,487 |
-$30,197,722 |
241,157 |
-94% |
Point72 Asset Management, L.P. |
30 Jun 2025 |
| CFLT |
Confluent, Inc. |
Class A Common Stock, par value $0.00001 per share |
0.1% |
$5,589,991 |
-$527,903,079 |
183,700 |
-99% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| ANNX |
Annexon, Inc. |
Common Stock, par value $0.001 per share |
0.1% |
$181,317 |
|
95,430 |
|
Point72 Asset Management, L.P. |
31 Mar 2025 |
| PLRX |
PLIANT THERAPEUTICS, INC. |
Common Stock, par value $0.0001 per share |
0.1% |
$56,775 |
-$4,926,946 |
46,537 |
-99% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| WHWK |
Whitehawk Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
0% |
$7,834 |
-$2,256,445 |
5,087 |
-100% |
Point72 Asset Management, L.P. |
31 Mar 2025 |
| KALA |
KALA BIO, Inc. |
Common Stock, par value $0.001 per share |
0% |
$393 |
-$717,340 |
257 |
-100% |
Point72 Asset Management, L.P. |
30 Sep 2025 |
| SYRS |
Syros Pharmaceuticals, Inc. |
Common Stock, par value $0.001 per share |
0% |
$14.88 |
|
496 |
|
Point72 Asset Management, L.P. |
31 Dec 2024 |
| FGNX |
FG Nexus Inc. |
Common Stock, par value $0.001 per share |
0% |
$0 |
-$12,960,000 |
0 |
-100% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| SHLS |
Shoals Technologies Group, Inc. |
Class A Common Stock, par value $0.00001 per share |
0% |
$0 |
-$52,172,962 |
0 |
-100% |
Point72 Asset Management, L.P. |
30 Jun 2025 |
| IKT |
Inhibikase Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
0% |
$0 |
|
0 |
|
Point72 Asset Management, L.P. |
31 Dec 2024 |
| CDMO |
Avid Bioservices, Inc. |
Common Stock, par value $0.001 per share |
0% |
$0 |
|
0 |
|
Point72 Asset Management, L.P. |
31 Dec 2024 |
| KRRO |
Korro Bio, Inc. |
Common Stock, par value $0.001 per share |
0% |
$0 |
-$7,343,976 |
0 |
-100% |
Point72 Asset Management, L.P. |
31 Dec 2025 |
| SGMT |
Sagimet Biosciences Inc. |
Series A Common Stock, par value $0.0001 per share |
0% |
$0 |
-$16,621,204 |
0 |
-100% |
Point72 Asset Management, L.P. |
30 Jun 2025 |
| TSBX |
Turnstone Biologics Corp. |
Common Stock, par value $0.001 per share |
0% |
$0 |
|
0 |
|
Point72 Asset Management, L.P. |
30 Sep 2025 |
| JOYY |
JOYY Inc. |
Class A Common Shares, par value US$0.00001 per share |
0% |
$0 |
|
0 |
|
Point72 Asset Management, L.P. |
31 Mar 2025 |
| APVO |
Aptevo Therapeutics Inc. |
Common Stock, par value $0.001 per share |
0% |
$0 |
-$182,966 |
0 |
-100% |
Point72 Asset Management, L.P. |
31 Dec 2025 |